<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899847</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-15772</org_study_id>
    <secondary_id>SU-04142009-2259</secondary_id>
    <secondary_id>BMT201</secondary_id>
    <nct_id>NCT00899847</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI &amp; ATG</brief_title>
  <official_title>A Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant
      approach for patients with advanced stage multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Development of cell-based immunotherapy from allogeneic hematopoietic cell transplantation
      (HCT) is dependent upon stable T-cell engraftment and the success of this therapeutic
      approach is likely to be greatest when directed against a minimal rather than gross tumor
      burden. To this end, tandem transplants with high dose therapy and autologous hematopoietic
      cell transplantation (AHCT) for tumor cytoreduction followed by non-myeloablative
      allotransplant have been conducted. In myeloma, this tandem approach results in greater
      efficacy compared to conventional AHCT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Graft Versus Host Disease (GvHD)</measure>
    <time_frame>2 years after the last participant is enrolled.</time_frame>
    <description>To evaluate the incidence acute GvHD of this tandem autologous/allogeneic transplant setting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Engraftment After Auto-PBSC Transplant</measure>
    <time_frame>1 month</time_frame>
    <description>Engraftment is assessed as:
Neutrophil engraftment is &gt; 0.5 x 10⁹/L after cytopenia
Platelet engraftment is &gt; 20 x 10⁹/L after cytopenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Engraftment After Allo-PBSC Transplant</measure>
    <time_frame>1 month</time_frame>
    <description>Engraftment is assessed as:
Neutrophil engraftment is &gt; 0.5 x 10⁹/L after cytopenia
Platelet engraftment is &gt; 20 x 10⁹/L after cytopenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>Overall response rate (ORR) = Complete Response Rate (CRR) + Partial Response Rate (PRR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>1 year</time_frame>
    <description>Complete response rate (CRR) was assessed as all of:
Negative immunoflixation on the serum and urine
Disappearance of any soft tissue plasmacytomas
&lt; 5% plasma cells in bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response Rate (PRR)</measure>
    <time_frame>1 year</time_frame>
    <description>Partial response rate (PRR) was assessed as
&gt; 50% reduction in serum M-protein plus urine M-protein reduction by 90% or &lt; 200 mg/24 hr
If serum M-protein is not measurable, then &gt; 50% reduction in the involved serum free light chain
If involved serum free light chain is not measurable, then &gt; 50% reduction in the bone marrow plasma cell percentage + &gt; 50% reduction in the size of any soft tissue plasmacytoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>2 years after the last participant is enrolled</time_frame>
    <description>To evaluate the graft versus myeloma effect by monitoring rate of event-free survival (EFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years after the last participant is enrolled</time_frame>
    <description>To evaluate the graft versus myeloma effect by monitoring rate of overall survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Transplantation, Homologous</condition>
  <condition>Transplantation, Autologous</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Blood and Marrow Transplant (BMT)</condition>
  <arm_group>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous peripheral blood stem cells (auto-PBSC) transplantation</intervention_name>
    <description>Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.
and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>auto-PBPC</other_name>
    <other_name>Autologous peripheral blood progenitor cells (auto-PBPC) transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic peripheral blood stem cells (allo-PBSC) transplantation</intervention_name>
    <description>Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>allo-PBSC</other_name>
    <other_name>Allogeneic peripheral blood progenitor cells (allo-PBPC) transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.
Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.
Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection.</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>Neupogen</other_name>
    <other_name>Granulocyte colony-stimulating factor (G-CSF)</other_name>
    <other_name>r-metHuG-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate (CPM)</other_name>
    <other_name>CSP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-phenylalanine mustard (L-PAM)</other_name>
    <other_name>L-Sarcolysin phenylalanine mustard</other_name>
    <other_name>L-sarcolysine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CSP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total lymphoid irradiation</intervention_name>
    <description>Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>TLI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabbit anti-thymocyte globulin</intervention_name>
    <description>ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>Thymoglobulin</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil 250mg</intervention_name>
    <description>MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solumedrol</intervention_name>
    <description>Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>Solumedin</other_name>
    <other_name>Soludecadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.</description>
    <arm_group_label>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PARTICIPANT INCLUSION CRITERIA

          -  Stage II-III multiple myeloma or have progression after initial treatment of Stage I
             disease (Durie Salmon Staging). Patients with plasma cell leukemia are also included.

          -  Multiple myeloma / plasma cell leukemia diagnosis confirmed by pathology reviewed at
             Stanford University Medical Center.

          -  18 to ≤ 75 years of age

          -  Karnofsky Performance Status &gt; 70%.

          -  Corrected Carbon monoxide diffusing capacity (Dlco) &gt; 60%

          -  Left ventricle ejection fraction (LVEF) &gt; 50%.

          -  Alanine aminotransferase (ALT) ≤ 2 x normal

          -  Aspartate aminotransferase (AST) ≤ 2 x normal

          -  Total bilirubin ≤ 2 mg/dL, unless hemolysis or Gilbert's disease.

          -  Estimated creatinine clearance &gt; 50 mL/min.

          -  Identified related or unrelated Human leukocyte antigen (HLA)-identical donor or donor
             with one antigen/allele mismatch in (HLA-A, B, C or DRB1).

          -  Signed informed consent.

        DONOR INCLUSION CRITERIA

          -  At least 17 years of age

          -  HIV-seronegative

          -  Must be capable of giving signed, informed consent

          -  No contraindication to the administration of filgrastim

          -  Willing to have a central venous catheter placed for apheresis if peripheral veins are
             inadequate

        PARTICIPANT EXCLUSION CRITERIA

          -  Prior allogeneic hematopoietic cell transplantation

          -  Uncontrolled active infection

          -  Uncontrolled congestive heart failure or angina

          -  HIV-positive

          -  Pregnant or nursing

        DONOR EXCLUSION CRITERIA

          -  Serious medical or psychological illness

          -  Pregnant or lactating

          -  Prior malignancies within the last 5 years except for non-melanoma skin cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Kai Weng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <results_first_submitted>August 24, 2017</results_first_submitted>
  <results_first_submitted_qc>September 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2017</results_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Wen-Kai Weng</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine (Blood and Marrow Transplantation)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Autologous-Allogeneic Hematopoietic Stem Cell Transplant</title>
          <description>Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of suitable allogeneic donor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Autologous-Allogeneic Hematopoietic Stem Cell Transplant</title>
          <description>A high-dose sequential chemotherapy approach with cyclophosphamide and etoposide followed by granulocyte colony stimulating factor (G-CSF) for collection of peripheral blood progenitor cells as well as for cytoreduction. Total Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).The preparatory regimens use BCNU and melphalan.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="33" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Graft Versus Host Disease (GvHD)</title>
        <description>To evaluate the incidence acute GvHD of this tandem autologous/allogeneic transplant setting</description>
        <time_frame>2 years after the last participant is enrolled.</time_frame>
        <population>Due to the significance of the allo-PBSC transplant as a component to the treatment plan, participants who did not receive allo-PBSC are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous-Allogeneic Hematopoietic Stem Cell Transplant</title>
            <description>A high-dose sequential chemotherapy approach with cyclophosphamide and etoposide followed by granulocyte colony stimulating factor (G-CSF) for collection of peripheral blood progenitor cells as well as for cytoreduction. Total Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).The preparatory regimens use BCNU and melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Graft Versus Host Disease (GvHD)</title>
          <description>To evaluate the incidence acute GvHD of this tandem autologous/allogeneic transplant setting</description>
          <population>Due to the significance of the allo-PBSC transplant as a component to the treatment plan, participants who did not receive allo-PBSC are not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Engraftment After Auto-PBSC Transplant</title>
        <description>Engraftment is assessed as:
Neutrophil engraftment is &gt; 0.5 x 10⁹/L after cytopenia
Platelet engraftment is &gt; 20 x 10⁹/L after cytopenia</description>
        <time_frame>1 month</time_frame>
        <population>Includes all study participants</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous-Allogeneic Hematopoietic Stem Cell Transplant</title>
            <description>Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Engraftment After Auto-PBSC Transplant</title>
          <description>Engraftment is assessed as:
Neutrophil engraftment is &gt; 0.5 x 10⁹/L after cytopenia
Platelet engraftment is &gt; 20 x 10⁹/L after cytopenia</description>
          <population>Includes all study participants</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophil Engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="10" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="10" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Engraftment After Allo-PBSC Transplant</title>
        <description>Engraftment is assessed as:
Neutrophil engraftment is &gt; 0.5 x 10⁹/L after cytopenia
Platelet engraftment is &gt; 20 x 10⁹/L after cytopenia</description>
        <time_frame>1 month</time_frame>
        <population>Due to the less intensive conditioning before allo-PBSC, only 2 participants experienced cytopenia, and thus only 2 participants could be evaluated for engraftment after allo-PBSC.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous-Allogeneic Hematopoietic Stem Cell Transplant</title>
            <description>Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Engraftment After Allo-PBSC Transplant</title>
          <description>Engraftment is assessed as:
Neutrophil engraftment is &gt; 0.5 x 10⁹/L after cytopenia
Platelet engraftment is &gt; 20 x 10⁹/L after cytopenia</description>
          <population>Due to the less intensive conditioning before allo-PBSC, only 2 participants experienced cytopenia, and thus only 2 participants could be evaluated for engraftment after allo-PBSC.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophil Engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="24" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="10" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Overall response rate (ORR) = Complete Response Rate (CRR) + Partial Response Rate (PRR)</description>
        <time_frame>1 year</time_frame>
        <population>Includes all study participants</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</title>
            <description>Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>Overall response rate (ORR) = Complete Response Rate (CRR) + Partial Response Rate (PRR)</description>
          <population>Includes all study participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Rate (CRR)</title>
        <description>Complete response rate (CRR) was assessed as all of:
Negative immunoflixation on the serum and urine
Disappearance of any soft tissue plasmacytomas
&lt; 5% plasma cells in bone marrow</description>
        <time_frame>1 year</time_frame>
        <population>Includes all study participants</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous-Allogeneic Hematopoietic Stem Cell Transplant</title>
            <description>Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate (CRR)</title>
          <description>Complete response rate (CRR) was assessed as all of:
Negative immunoflixation on the serum and urine
Disappearance of any soft tissue plasmacytomas
&lt; 5% plasma cells in bone marrow</description>
          <population>Includes all study participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Response Rate (PRR)</title>
        <description>Partial response rate (PRR) was assessed as
&gt; 50% reduction in serum M-protein plus urine M-protein reduction by 90% or &lt; 200 mg/24 hr
If serum M-protein is not measurable, then &gt; 50% reduction in the involved serum free light chain
If involved serum free light chain is not measurable, then &gt; 50% reduction in the bone marrow plasma cell percentage + &gt; 50% reduction in the size of any soft tissue plasmacytoma.</description>
        <time_frame>1 year</time_frame>
        <population>Includes all study participants</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous-Allogeneic Peripheral Blood Stem Cell Transplant</title>
            <description>Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Response Rate (PRR)</title>
          <description>Partial response rate (PRR) was assessed as
&gt; 50% reduction in serum M-protein plus urine M-protein reduction by 90% or &lt; 200 mg/24 hr
If serum M-protein is not measurable, then &gt; 50% reduction in the involved serum free light chain
If involved serum free light chain is not measurable, then &gt; 50% reduction in the bone marrow plasma cell percentage + &gt; 50% reduction in the size of any soft tissue plasmacytoma.</description>
          <population>Includes all study participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival (EFS)</title>
        <description>To evaluate the graft versus myeloma effect by monitoring rate of event-free survival (EFS)</description>
        <time_frame>2 years after the last participant is enrolled</time_frame>
        <population>Includes all study participants</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous-Allogeneic Hematopoietic Stem Cell Transplant</title>
            <description>A high-dose sequential chemotherapy approach with cyclophosphamide and etoposide followed by granulocyte colony stimulating factor (G-CSF) for collection of peripheral blood progenitor cells as well as for cytoreduction. Total Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).The preparatory regimens use BCNU and melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival (EFS)</title>
          <description>To evaluate the graft versus myeloma effect by monitoring rate of event-free survival (EFS)</description>
          <population>Includes all study participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="14" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>To evaluate the graft versus myeloma effect by monitoring rate of overall survival (OS)</description>
        <time_frame>2 years after the last participant is enrolled</time_frame>
        <population>Includes all study participants</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous-Allogeneic Hematopoietic Stem Cell Transplant</title>
            <description>A high-dose sequential chemotherapy approach with cyclophosphamide and etoposide followed by granulocyte colony stimulating factor (G-CSF) for collection of peripheral blood progenitor cells as well as for cytoreduction. Total Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).The preparatory regimens use BCNU and melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>To evaluate the graft versus myeloma effect by monitoring rate of overall survival (OS)</description>
          <population>Includes all study participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="28" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Autologous-Allogeneic Hematopoietic Stem Cell Transplant</title>
          <description>A high-dose sequential chemotherapy approach with cyclophosphamide and etoposide followed by granulocyte colony stimulating factor (G-CSF) for collection of peripheral blood progenitor cells as well as for cytoreduction. Total Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).The preparatory regimens use BCNU and melphalan.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wen-Kai Weng, MD; Associate Professor of Medicine</name_or_title>
      <organization>Stanford University School of Med</organization>
      <phone>650-723-7689</phone>
      <email>wkweng@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

